AU2014284224B2 - Free base crystals - Google Patents
Free base crystals Download PDFInfo
- Publication number
- AU2014284224B2 AU2014284224B2 AU2014284224A AU2014284224A AU2014284224B2 AU 2014284224 B2 AU2014284224 B2 AU 2014284224B2 AU 2014284224 A AU2014284224 A AU 2014284224A AU 2014284224 A AU2014284224 A AU 2014284224A AU 2014284224 B2 AU2014284224 B2 AU 2014284224B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- crystal
- free base
- pyrazolo
- imidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BBIPVJCGIASXJB-PKTZIBPZSA-N CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Nc2ccccc2)c11)C1=O Chemical compound CN(C1=N[C@H](CCC2)[C@H]2N1c1n[n](Cc(cc2)ccc2-c2cccc(F)n2)c(Nc2ccccc2)c11)C1=O BBIPVJCGIASXJB-PKTZIBPZSA-N 0.000 description 3
- UNRBJEOYYDGFGE-UHFFFAOYSA-N CN(C(c1c[n](Cc(cc2)ccc2-c2cccc(F)n2)nc1N1)=O)C1=O Chemical compound CN(C(c1c[n](Cc(cc2)ccc2-c2cccc(F)n2)nc1N1)=O)C1=O UNRBJEOYYDGFGE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838105P | 2013-06-21 | 2013-06-21 | |
| US61/838,105 | 2013-06-21 | ||
| US201361919424P | 2013-12-20 | 2013-12-20 | |
| US61/919,424 | 2013-12-20 | ||
| PCT/US2014/043422 WO2014205354A2 (en) | 2013-06-21 | 2014-06-20 | Free base crystals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014284224A1 AU2014284224A1 (en) | 2016-02-11 |
| AU2014284224B2 true AU2014284224B2 (en) | 2019-08-01 |
Family
ID=52105535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014284224A Active AU2014284224B2 (en) | 2013-06-21 | 2014-06-20 | Free base crystals |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9630971B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3010509B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6865036B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160040522A (cg-RX-API-DMAC7.html) |
| CN (3) | CN105658222A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014284224B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015032132B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2916393C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2894770T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL267331B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2015017972A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2675851C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014205354A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| CN105658222A (zh) | 2013-06-21 | 2016-06-08 | 细胞内治疗公司 | 游离碱晶体 |
| JP7612672B2 (ja) | 2019-09-03 | 2025-01-14 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規化合物 |
| WO2021226407A1 (en) * | 2020-05-06 | 2021-11-11 | Intra-Cellular Therapies, Inc. | Free base crystals |
| WO2022026417A1 (en) * | 2020-07-26 | 2022-02-03 | Intra-Cellular Therapies, Inc. | Novel uses |
| EP4395767A4 (en) * | 2021-09-03 | 2025-07-23 | Intra Cellular Therapies Inc | CO-CRYSTALS |
| JP2025504555A (ja) * | 2022-01-27 | 2025-02-12 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規組成物 |
| WO2023233410A1 (en) * | 2022-06-02 | 2023-12-07 | Biosight Ltd. | Crystalline form of aspacytarabine intermediate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009075784A1 (en) * | 2007-12-06 | 2009-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2013192556A2 (en) * | 2012-06-21 | 2013-12-27 | Intra-Cellular Therapies, Inc. | Salt crystals |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| US5471001A (en) * | 1994-12-15 | 1995-11-28 | E. I. Du Pont De Nemours And Company | Crystallization of adipic acid |
| GB9624615D0 (en) * | 1996-11-26 | 1997-01-15 | Zeneca Ltd | Chrystallisation process |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| EP1481969B1 (en) | 2002-02-08 | 2011-01-19 | Ono Pharmaceutical Co., Ltd. | Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| WO2004087906A1 (en) * | 2003-03-31 | 2004-10-14 | Pfizer Products Inc. | Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| JP2007504230A (ja) * | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態 |
| US7868176B2 (en) * | 2004-09-27 | 2011-01-11 | Acadia Pharmaceuticals, Inc. | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation |
| ES2645371T3 (es) | 2005-06-06 | 2017-12-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| US20120070443A1 (en) * | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
| JP5784501B2 (ja) | 2008-12-06 | 2015-09-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| ES2638912T3 (es) | 2008-12-06 | 2017-10-24 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
| US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
| EP2434895A4 (en) * | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| EP2485771A4 (en) | 2009-10-08 | 2014-11-12 | Intra Cellular Therapies Inc | TRACER AND METHODS TAGGED ON PHOSPHODIESTERASE 1 |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN105658222A (zh) | 2013-06-21 | 2016-06-08 | 细胞内治疗公司 | 游离碱晶体 |
-
2014
- 2014-06-20 CN CN201480046150.4A patent/CN105658222A/zh active Pending
- 2014-06-20 ES ES14812994T patent/ES2894770T3/es active Active
- 2014-06-20 CN CN202110144523.3A patent/CN112851683A/zh active Pending
- 2014-06-20 KR KR1020167001273A patent/KR20160040522A/ko not_active Ceased
- 2014-06-20 EP EP14812994.3A patent/EP3010509B1/en active Active
- 2014-06-20 AU AU2014284224A patent/AU2014284224B2/en active Active
- 2014-06-20 CA CA2916393A patent/CA2916393C/en active Active
- 2014-06-20 BR BR112015032132-1A patent/BR112015032132B1/pt active IP Right Grant
- 2014-06-20 WO PCT/US2014/043422 patent/WO2014205354A2/en not_active Ceased
- 2014-06-20 US US14/900,589 patent/US9630971B2/en active Active
- 2014-06-20 IL IL267331A patent/IL267331B2/en unknown
- 2014-06-20 RU RU2016101630A patent/RU2675851C2/ru active
- 2014-06-20 CN CN201910526464.9A patent/CN110498800A/zh active Pending
- 2014-06-20 JP JP2016521847A patent/JP6865036B2/ja active Active
- 2014-06-20 EP EP20165092.6A patent/EP3702358A1/en active Pending
- 2014-06-20 MX MX2015017972A patent/MX2015017972A/es active IP Right Grant
- 2014-06-20 KR KR1020217030964A patent/KR102430126B1/ko active Active
-
2015
- 2015-12-21 IL IL243269A patent/IL243269B/en active IP Right Grant
- 2015-12-21 MX MX2020001628A patent/MX2020001628A/es unknown
-
2019
- 2019-06-04 JP JP2019104412A patent/JP2019189618A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009075784A1 (en) * | 2007-12-06 | 2009-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2013192556A2 (en) * | 2012-06-21 | 2013-12-27 | Intra-Cellular Therapies, Inc. | Salt crystals |
Non-Patent Citations (4)
| Title |
|---|
| BOWKER ET AL, A Procedure for Salt Selection and Optimization, HANDBOOK OF PHARMACEUTICAL SALTS : PROPERTIES, SELECTION, AND USE, ZÜRICH : VERL. HELVETICA CHIMICA ACTA ; PAGE(S) 162 - 173, (2002-01-01), ISBN 978-3-906390-26-0 * |
| CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, (1998-01-01), vol. 198, ISSN 0340-1022, pages 163 - 208 * |
| HILFIKER R (EDITOR) ED - HILFIKER R, Polymorphism in the Pharmaceutical Industry, 2006-01-01, PAGE(S) 1 - 19, (2006-01-01), ISBN 978-3-527-31146-0 * |
| RICHARD J BASTIN ET AL, ORGANIC PROCESS RESEARCH AND DEVELOPMENT, AMERICAN CHEMICAL SOCIETY, US, vol. 4, no. 5, (2000-07-19), pages 427 - 435, (2000-07-19) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014284224B2 (en) | Free base crystals | |
| JP6853794B2 (ja) | 塩結晶 | |
| CN108699063A (zh) | 一种芦可替尼的合成工艺 | |
| WO2018073574A1 (en) | Polymorphic forms of palbociclib | |
| US12435093B2 (en) | Free base crystals | |
| HK40036801A (en) | Process for preparing salts of a known pde1 inhibitor | |
| HK1223848B (en) | Free base crystals | |
| HK40090878A (zh) | 用於制备1-甲基-6-[6-r2-5-甲基-8-(甲基氨基)-4-[(3as，6as)-5-甲基-2，3，3a，4，6，6a-六氢吡咯并[2，3-c]吡咯-1-基]-9h-吡啶并[2，3-b]吲哚-3-基]-4-氧代-1，8-萘啶-3-甲酸盐酸盐的方法 | |
| HK1247191A1 (en) | Salt crystals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |